Avid Bioservices Inc (CDMO)

[revenue_monster]

To simply state even with the supporting info that a competing product targeting the same indication will have zero impact to PPHM enrollment is reckless. Competition is brutal in biotech especially against big boys. Patients might feel compelled to opt for opdivo vs doce/ Bavi due to recent results, as well as moving away from standard chemo treatments. Granted more detail must be shared. Jmo Again Im not saying a profound impact but it's greater than zero my friend.